Time: 0 second

SOE 038: Renal Replacement Therapy 3

Introduction

A 48-year-old man is admitted to the intensive care unit with severe biliary sepsis. He is requiring high dose noradrenaline and vasopressin to maintain a MAP >65mmHg.

Case Information

Blood results show:

Question No. 3

Q: In the absence of emergency indications what are the advantages and disadvantages with early and late timing of RRT initiation?

Answer No. 3

Early Initiation
  • May confer benefit, in particular in circumstances in which there is a perception that recovery from AKI is not imminent
  • Can theoretically facilitate more rapid correction of electrolyte and acid-base derangements and control of uraemia and mitigate fluid accumulation
  • Would prevent the occurrence of overt complications of AKI
  • May limit worsening of non-renal organ dysfunction (potential kidney-organ interactions)
  • Will result in initiation of RRT in a significant portion of patients who may have regained renal function with conservative management
Late Initiation
  • Has not been shown to lead to worse outcomes than early initiation
  • Prevents complications of RRT in subset of patients that did not require it:
    • Insertion of dialysis catheters
    • Exposure to extracorporeal circuits
    • Clearance of nutrients and medication
    • Iatrogenic haemodynamic instability
  • Reduces healthcare costs by limiting bedside workload and resource utilisation

Question No. 4

Q: What is the evidence in regard to early or late initiation of RRT?

Answer No. 4

Intervention
Population
Conclusion

RCT: ELAIN


Zarbock et al
JAMA (2016)

View Paper
  • Early vs. Late initiation of RRT
  • Early: Within 8 hours of meeting KDIGO stage 2 AKI
  • Late: Within 12 hours of meeting KDIGO stage 3 AKI or emergency indication
  • 231 patients with AKI and either severe sepsis or requiring catecholamine infusion
  • Early group showed significantly lower mortality at 90 days (39.3% vs. 54.7%, p=0.03)
The Bottom Line Review

RCT: AKIKI


Gaudry et al
NEJM (2016)

View Paper
  • Early vs. Late initiation of RRT
  • Early: Immediately upon meeting KDIGO stage 3 AKI criteria
  • Late: If oliguric 72 hours after meeting KDIGO stage 3 AKI criteria or emergency indications
  • 620 patients with AKI requiring mechanical ventilation or catecholamine infusion
  • No difference in mortality between early and late group (48.5% vs 49.7%, p=0.79)
  • In delayed group 49% did not require RRT
The Bottom Line Review

RCT: IDEAL-ICU


Barbar et al
NEJM (2018)

View Paper
  • Early vs. Late initiation of RRT
  • Early: within 12-hours of meeting failure by RIFLE criteria
  • Late: after 48-hours of meeting failure by RIFLE criteria if no renal recovery or emergency indications
  • 488 patients with severe AKI and septic shock
  • No difference in mortality between early and late group (58% vs 54%, p=0.38)
  • In delayed group:
    • 38% did not require RRT
    • 17% met indications for emergency RRT
    The Bottom Line Review

Question No. 5

Q: What factors should be taken into account when determining whether initiation of RRT is appropriate for a patient in AKI?

Answer No. 5

  •  In the absence of emergency indications:
    • Current evidence does not firmly confirm advantages of either an early or late initiation of RRT
    •  Most evidence supports the use of a “wait and see” attitude without leading to worse outcomes
  • Patient should be considered as a whole (Table adapted from Macedo et al):

Severity of Illness & Trajectory

  • AKI severity and trend
  • Severity of electrolyte and acid base disorder
  • Fluid balance and symptoms of overload
  • Presence of other organ dysfunction impacted by AKI / fluid overload

Necessity of RRT

  • Likelihood of early recovery of kidney function without RRT
  • Underlying comorbidities impacted by AKI / fluid overload
  • Associated acute organ dysfunction

Risks of RRT

  • Vascular access
  • Haemodynamic instability
  • Infection
  • Clearance of trace elements / vitamins / drugs
  • Immobilisation

Other Factors

  • Patient and family wishes
  • Overall goals of care
  • Availability of machines and nursing staff
  • Healthcare costs

Question No. 6

Q: What are the basic components of CRRT that need prescribing in ICU?

Answer No. 6

Component
Choice
Blood Flow Rate
  • Blood flow rates are typically slower than in intermittent dialysis (150-200mL/min)
  • Generally, the faster the flow, the more efficient the dialysis.
Dialysate or Replacement Fluid Composition
  • The specific fluid is based on the metabolic parameters of the patient, including the patient’s acid-base status and serum potassium concentration
  • Typical flow rates range from 500mL/min to 800mL/min
Replacement Fluid Pre/Post Dilution Ratio
  • The proportion of replacement fluid delivered before or after the filter
  • Typically started with 30% pre- and 70% post-dilution
Effluent Rate (Dose)
  • Dosing is weight based and is typically prescribed at a dose ranging from 20 mL/kg/hr to 35 mL/kg/hr
Fluid Removal Goal
  • This is the amount of fluid to be removed from the patient over the course of the session
  • Determined by clinical assessment of the patient’s volume status.
Anticoagulation
  • Clotting within the dialysis circuit can result in significant blood loss
  • Heparin is typically used unless the patient has a contraindication
  • An alternative to heparin anticoagulation often used with CRRT is regional citrate anticoagulation, in which citrate is administered to chelate calcium, a critical cofactor in the clotting cascade

Question No. 7

Q: What effect do changes in the blood flow rate have?

Answer No. 7

Advantages
Disadvantages
High Blood Flows
  • A lower filtration fraction required thus reducing the risk of filter clotting
  • Easier to match ultrafiltration rates and therefore fluid removal targets
  • Increased risk of haemodynamic instability
  • Increased risk of hypothermia or haemolysis
  • Requires well-functioning access to prevent high suction pressures developing
Low Blood Flows
  • Reduced haemodynamic instability
  • Reduced risk of filter related complications
  • Lower suction pressures needed to achieve flow rates
  • Increased risk of filter clotting due to high filtration fractions
  • More challenging to meet fluid removal targets

Question No. 8

Q: What evidence exists to determine the optimum ‘dose’ of CRRT? 

Answer No. 8

Intervention
Population
Conclusion

RCT: ELAIN


Zarbock et al
JAMA (2016)

View Paper
  • Early vs. Late initiation of RRT
  • Early: Within 8 hours of meeting KDIGO stage 2 AKI
  • Late: Within 12 hours of meeting KDIGO stage 3 AKI or emergency indication
  • 231 patients with AKI and either severe sepsis or requiring catecholamine infusion
  • Early group showed significantly lower mortality at 90 days (39.3% vs. 54.7%, p=0.03)
The Bottom Line Review

RCT: AKIKI


Gaudry et al
NEJM (2016)

View Paper
  • Early vs. Late initiation of RRT
  • Early: Immediately upon meeting KDIGO stage 3 AKI criteria
  • Late: If oliguric 72 hours after meeting KDIGO stage 3 AKI criteria or emergency indications
  • 620 patients with AKI requiring mechanical ventilation or catecholamine infusion
  • No difference in mortality between early and late group (48.5% vs 49.7%, p=0.79)
  • In delayed group 49% did not require RRT
The Bottom Line Review

RCT: IDEAL-ICU


Barbar et al
NEJM (2018)

View Paper
  • Early vs. Late initiation of RRT
  • Early: within 12-hours of meeting failure by RIFLE criteria
  • Late: after 48-hours of meeting failure by RIFLE criteria if no renal recovery or emergency indications
  • 488 patients with severe AKI and septic shock
  • No difference in mortality between early and late group (58% vs 54%, p=0.38)
  • In delayed group:
    • 38% did not require RRT
    • 17% met indications for emergency RRT
    The Bottom Line Review

Question No. 9

Q: What is difference between prescribed and delivered dose? What dose should be prescribed?

Answer No. 9

  • There may be a significant difference between the prescribed ‘dose’ and that which is actually delivered – estimated using clearance equations to be 73% in practice
  • Due to a number of factors:
    • Treatment downtime due to filter clotting
    • Technical problems such as boor blood flow and recirculation
    • Reduced filter efficacy over time
    • Effects of pre-dilution
  • It is recommended that a dose of at least 35 ml/kg/h (post-dilution) is prescribed for CRRT
  • This ensures that an adequate dose of CRRT is delivered despite downtimes and other limiting factors

Question No. 10

Q: Why has a higher dose not shown to improve outcomes?

Answer No. 10

  • Increasing the dose may cause loss of essential molecules and thus affect outcome:
    • Antibiotics – many significantly cleared by RRT
    • Amino acids and proteins
    • Micronutrients (vitamins, selenium, folic acid)

Question No. 11

Q: What is the replacement fluid and what is it composed of?

Answer No. 11

  • Replacement fluid is given to replace the fraction of fluid which has been produced as effluent
    • The addition of fluid dilutes the concentration of solutes in excess in the plasma
    • The addition of solutes in the fluid can increase the concentration of solutes that are deplete in the plasma
  • They consist of a balanced salt solution with a molecule used to buffer acid – commonly either lactate or bicarbonate
  • Individual components vary but should contain:
    • Sodium 140 mmol/l
    • Chloride 108–112 mmol/l
    • Potassium 0–4 mmol/l
    • Calcium 1.5–1.75 mmol/l
    • Magnesium 0.5–0.75 mmol/l

Question No. 12

Q: Does the buffer make a difference?

Answer No. 12

  • There is no conclusive evidence of a benefit on survival or renal outcome with either bicarbonate or renal outcomes
  • Both types have advantages and disadvantages:

Bicarbonate Buffer

Lactate Buffer

  • May result in better control of acidaemia
  • May result in improved cardiovascular stability
  • Unstable in solution, need to be prepared just prior to use
  • More expensive
  • Cheaper than bicarbonate buffer
  • Longer shelf life
  • Can result in rise in serum lactate:
    • Lactate intolerance defined by rise in lactate >5 mmol/L
    • Should be switched to bicarbonate buffer

Question No. 13

Q: Which factors effect the pharmacokinetics of drugs administered whilst patients are receiving RRT?

Answer No. 13

Drug Factors
  • Protein binding:
    • Highly protein bound drugs (e.g. warfarin, diazepam, propranolol and phenytoin) are only cleared by RRT in small amounts
  • Molecular weight:
    • Larger molecules cleared less effectively by diffusive therapies
Therapy Factors
  • Timing of RRT:
    • Drugs given between sessions will not be cleared until the subsequent session
  • Dose of RRT:
    • Reduced flow rates / shorter sessions will decrease clearance of drugs
  • Membrane permeability
Patient Factors
  • Residual GFR and urine production
  • Hypoalbuminaemia

Question No. 14

Q: How should drugs be dosed during RRT?

Answer No. 14

  • Dosing during RRT can be challenging given the numerous factors needed to be accounted for:
    • Should not simply be dosed for reduced GFR
    • Nomograms developed for use in stable patients on IHD can result in significant under-dosing
  • Drug levels should be measured to aid dosing whenever possible
  • In the absence of drug levels:
    • ‘Bedside’ dosing guidelines should be used (e.g. ‘Renal Drug Handbook’)
    • Expert pharmacist help should be sought when possible

Review:

Total Score: /13

Total Time: